Ultragenyx

Yahoo Finance • 14 days ago

Suspect arrested after stabbing spree in downtown Seattle

Police arrested a man suspected of stabbing five people on the streets of downtown Seattle on Friday and believe he may be the same person responsible for five other stabbings in the same Chinatown area since early on Thursday morning, pol... Full story

Yahoo Finance • 6 months ago

Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical Inc. Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) with maintenance of glucose control Company will host investor call today at 5:00 p.m... Full story

Yahoo Finance • 6 months ago

Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells

Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical (NASDAQ:RARE) over the use of cells taken from Lacks’ body in the 1950s,... Full story

Yahoo Finance • 7 months ago

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc. NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies evaluating se... Full story

Yahoo Finance • 9 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Pharmaceutical Inc. NOVATO, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and u... Full story

Yahoo Finance • 9 months ago

Ultragenyx Pharmaceutical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line

Ultragenyx Pharmaceutical (NASDAQ:RARE) Full Year 2023 Results Key Financial Results Revenue: US$434.2m (up 20% from FY 2022). Net loss: US$606.6m (loss narrowed by 14% from FY 2022). US$8.25 loss per share (improved from US$10.12 loss i... Full story

Yahoo Finance • 9 months ago

15 Best Strong Buy Stocks To Invest In

In this piece, we will take a look at the 15 best strong buy stocks to invest in. If you want to skip our overview of analyst ratings and the finance industry, then you can take a look at the 5 Best Strong Buy Stocks To Invest In. The fin... Full story

Yahoo Finance • 11 months ago

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Pharmaceutical Inc. NOVATO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the National Institute for Health and Care Excellence (NICE) has issued a final draft guid... Full story

Yahoo Finance • 11 months ago

Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome

Ultragenyx Pharmaceutical Inc. Data from at least 20 patients enrolled in dose expansion cohorts anticipated in the first half of 2024 NOVATO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a bio... Full story

Yahoo Finance • 11 months ago

Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Ultragenyx Pharmaceutical Inc. NOVATO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious ra... Full story

Yahoo Finance • 11 months ago

13 Most Promising Future Stocks To Buy According To Hedge Funds

In this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds. If you want to skip our overview of the latest stock market news, then you can take a look at the 5 Most Promising Future Stocks To Buy. I... Full story

Yahoo Finance • last year

Ultragenyx to Participate at Investor Conferences in November

6th Annual Evercore ISI HealthCONxon November 28 in Miami Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City NOVATO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE),... Full story

Yahoo Finance • last year

Ultragenyx to Participate in the Jefferies London Healthcare Conference

NOVATO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic disea... Full story

Yahoo Finance • last year

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

ROMA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), azienda biofarmaceutica focalizzata sullo sviluppo e la commercializzazione di nuove terapie per malattie genetiche rare e ultra rare, ha annunciato o... Full story

Yahoo Finance • last year

12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds

In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massiv... Full story

Yahoo Finance • last year

Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. Third quarter 2023 total revenue of $98.1 million, Crysvita® revenue of $74.9 million and Dojolvi® revenue of $16.6 million Reaffirmed 2023 expected total revenue guidance between $425 million to $450 milli... Full story

Yahoo Finance • last year

Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update

NOVATO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseas... Full story

Yahoo Finance • last year

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments a... Full story

Yahoo Finance • last year

Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

NOVATO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today annou... Full story

Yahoo Finance • last year

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

NOVATO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today annou... Full story